Duchenne muscular dystrophy (DMD) is the most common and lethal genetic muscle disorder lacking a curative treatment. We wish to use the dystrophin-deficient golden retriever muscular dystrophy (GRMD) dog, a canine model of DMD, to investigate adeno-associated virus (AAV) vectormediated minidystrophin gene therapy. The dog model is useful in evaluating vector dose requirement and immunological consequences owing to its large size and outbred nature. In this study, we have cloned and constructed a canine minidystrophin gene vector. Owing to limited availability of the GRMD dogs, here we first examined the functions and therapeutic effects of the canine minidystrophin in the mdx mouse model. We observed efficient minigene expression without cellular immune responses in mdx mice after AAV1-cMinidys vector intramuscular injection. We also observed restoration of the missing dystrophin-associated protein complex (DPC) onto the sarcolemma, including sarcoglycans and dystrobrevin, and a partial restoration of a-syntrophin and neural nitric oxide synthase (nNOS). In addition, minidystrophin treatment ameliorated dystrophic pathology, such as fibrosis and myofiber central nucleation (CN). CN remained minimal (o2%) after AAV injection in the neonatal mdx mice and was reduced from more than 75% to about 25% after AAV injection in adult mdx mice. Finally, in vivo cell membrane leakage test with Evans blue dye showed that the canine minidystrophin could effectively protect the myofiber plasma membrane integrity. Our results, thus, demonstrated the functionality and therapeutic potential of the canine minidystrophin and paved its way for further testing in the GRMD dog model.
Introduction
Muscular dystrophy represents a group of skeletal muscle diseases that are characterized primarily by progressive muscle wasting and weakness. Duchenne muscular dystrophy (DMD) is the most common, disabling and lethal of these genetic muscle disorders, afflicting one of every 3500 males. Pathological signs of DMD often appear around 2 years of age. The progressive muscle weakness and degeneration continues unabated with the patient being confined to a wheelchair in their early teens, and death occurring by their early 20s due to respiratory or cardiac failure. 1 There are currently no curative treatments available for DMD. Pharmacologic treatments that are being applied to DMD patients include corticosteroids such as prednisone, but only with partial improvement in muscle strength and function. 2 Long-term use of the steroids is associated with serious side effects. Non-pharmacologic treatments, such as physical and surgical therapies offer limited relief to the patients.
Duchenne muscular dystrophy is a genetic disease caused by mutations in the X-linked dystrophin gene, 3 which encodes a large submembrane protein, dystrophin, in both skeletal and cardiac muscle cells. DMD is recessive and monogenic, and therefore is considered a good candidate for gene therapy. The mdx mouse is a commonly used rodent model, which contains a premature stop codon in the dystrophin gene that results in the lack of dystrophin protein and the loss of the dystrophin-associated protein complex (DPC). We 4, 5 and others [6] [7] [8] [9] have previously reported that in the mdx mouse model, adeno-associated virus (AAV) vectors carrying miniaturized dystrophin genes can effectively protect the muscles from dystrophic pathologies, and improve muscle contractile force.
Encouraged by the therapeutic efficacies in the mdx mice, we wished to evaluate AAV-minidystrophin gene therapy in the golden retriever muscular dystrophy (GRMD) dogs. This large animal model of DMD offers a number of advantages that are not available to the mdx mice. 10, 11 Besides muscle histopathology, the GRMD dogs exhibit clinical signs closely mimicking those observed in humans, for example, muscle atrophy, contractures, overt cardiomyopathy, premature death, and so on. More importantly, the dogs also have a much larger body mass than the mice, making the dogs more relevant to human DMD patients when assessing therapeutic doses of AAV vectors. These features allow for stringent test of in vivo gene delivery by AAV, and also serve as a more reliable predictor for clinical scenarios.
Recent reports showed that both normal and GRMD dogs had mounted robust cellular immune responses against the reporter genes, such as the Lac-Z, and also a human version of microdystrophin gene after intramuscular gene delivery by AAV vectors. [12] [13] [14] Our own preliminary experiment with a human minidystrophin gene in the GRMD dogs has met the same fate (unpublished data). Such robust cellular immune responses have not been seen previously in the mice and other rodents, suggesting that the GRMD dog is a more challenging model for gene therapy studies. In lieu of the above results, we reasoned in this study that it is necessary to clone and construct a miniature version of the canine dystrophin gene and test it in AAV vectors. Owing to very limited availability of the GRMD dogs, we opted to first examine the canine minigene in the mdx mice by intramuscular injection to see if it is biologically functional and therapeutic in the mouse model, before it could be used in the GRMD dogs. Our results showed that the canine minidystrophin is highly functional in restoring the missing muscle membrane proteins and muscle cell membrane integrity. More importantly, the canine minigene is also effective in protecting the dystrophic muscles from degeneration and histopathology in the mdx mice. These results justify and support further studies with the canine minigene in the DMD dogs.
Results

Cloning and construction of the AAV1-cMinidys vector
The dystrophin gene, whether human or canine, is extraordinarily large with coding sequences larger than 11 kb. In our previous studies, we abbreviated the essential functional units of the human dystrophin gene down to less than 4.2 kb and showed that these minidystrophin vectors successfully ameliorated the dystrophic phenotypes. 4, 5 As depicted in Figure 1 , in this study, we followed the same rationale and constructed a truncated canine minidystrophin gene (3.8 kb) consisted of the following elements: N terminus, hinge1, rods 1, 2, 22, 23, 24, hinge 4 and CR domain (Figure 1a ). This canine minigene was under the transcriptional control by a human cytomegalovirus immediate-early gene (CMV) promoter for strong and long-term gene expression in the muscle. Before the in vivo gene transfer experiments, we transfected a few subclones of the minigene plasmid construct into 293 cells to confirm by Western analysis that the correct dystrophin protein was synthesized ( Figure 1b) . The subclone represented in lanes 3 showed better expression with a molecular weight of 154 kDa, identical to that of the human minidystrophin protein positive control. Clone 3 was therefore selected and fully sequenced for further experiments. The vector was packaged in AAV1 vector 15 for efficient gene delivery in muscle and widespread expression in the mdx mouse model, which does not show the immune rejection to human minidystrophin or the LacZ reporter protein. Restoration of dystrophin-protein complex, a-syntrophin and neural nitric oxide synthase to sarcolemma
The lack of dystrophin on the sarcolemma of dystrophic muscles causes the lack or a dramatic reduction of the DPC, which contains dystroglycans, sarcoglycans, sarcospan, a-dystrobrevin and syntrophin and neural nitric oxide synthase (nNOS). 16, 17 These proteins interact with each other and serve as a mechanical link and possibly signaling partners to protect the myofibers. At 3 months, after AAV1-cMinidys vector injection into neonatal (10 day of age) mdx mice, immunoflurescent staining was performed on the cryo-thin-sections of the gastrocnemius muscles from the normal C57/B10 mice, the untreated mdx littermates and the AAV-treated mdx mice, at same age. As shown in Figure 2A , efficient expression of the canine minigene has effectively restored the missing sarcoglycan complex onto the sarcolemma. Counterstaining the cell nuclei in C57/B10 and the AAV-treated mdx mice showed the lack of central nucleation (CN), a pathological sign of muscle degeneration and regeneration. By contrast, the untreated mdx mice had extensive CN and lacked dystrophin and sarcoglycans on the sarcolemma.
Similar to our previous human minidystrophin constructs, the canine minidystrophin also had the entire distal CT domain deleted ( Figure 1a ). This deletion would also cause the loss of syntrophin-binding site, hence indirectly the nNOS association to the minidystrophin. We wished to examine if the nNOS is present or absent on the sarcolemma of AAV-treated mdx muscle, which had not been investigated in our previous human minidystrophin studies. 4 Immunoflurescent staining of the C57/B10 normal control muscle showed strong and clear presence of dystrophin, dystrobrevin, a-syntrophin as well as nNOS on the sarcolemma ( Figure 2B , panels a-d). As expected, the untreated control mdx muscle revealed the absence of dystrophin and the other three proteins we tested, including nNOS, whereas counterstaining of the cell nuclei with 4,6-diamidino-2-phenylindole (DAPI) showed extensive CN ( Figure 2B , panels e-h). A few dystrophin-revertant myofibers however displayed staining of dystrobreven, syntrophin and nNOS in the untreated mdx ( Figure 2B , highlighted by arrows). In contrast, the AAV1-cMinidys vectortreated mdx muscle revealed extensive presence of minidystrophin, along with dystrobrevin, and to our surprise, syntrophin and nNOS as well ( Figure 2B , panels i-l), though they are at a reduced level when compared to the wild-type C57B10 muscles ( Figure 2B , panels a-d). Higher magnification of consecutive sections showed clear membrane staining of those proteins and the lack of CN by DAPI counterstaining ( Figure 2B , Panels m-p). These data demonstrated for the first time that a mini-or microdystrophin protein in mdx muscle tissue could partially restore nNOS to the sarcolemma (see Discussion later).
Canine minidystrophin prevents and ameliorates muscle histopathology
We next investigated the ability of the AAV1-cMinidys vector to ameliorate the pathology in mdx mice. The disease onset in mdx mice begins with massive waves of myofiber degeneration/regeneration around 3 weeks of age. To see whether the pathological process can be halted, we tested adult mdx mice (2 months old) when the histopathology is already present. The mice were injected intramuscularly with the AAV1-cMinidys vector in one of their hindlegs, and the contralateral legs served as untreated controls. The muscles were collected at 1 and 3 months post-AAV1 vector injection for examination of dystrophin expression and histology. Although the age-matched C57/B10 normal mice control showed uniform dystrophin gene expression in all the myofibers with normal histology ( Figure 3A , panels a and e), the untreated mdx muscle showed no dystrophin expression and extensive CN and fibrotic infiltration ( Figure 3A , panels b and f). In contrast, muscles from AAV-treated adult mdx mice showed widespread and strong expression at both 1 and 3 months post-injection ( Figure 3A , panels c and d), along with improved muscle histology ( Figure 3A , panels g and h). Quantitative analysis of CN from 600 to 900 dystrophin-positive myofibers of the adult-age treated mdx mice showed reduction of CN from approximately 70% to less than 25% at both 1 and 3 months post-AAV1 vector injection ( Figure 3B ). Consistent with our previous data of human minidystrophin genes, the CN remained very low at less than 2% when the AAV1-cMinidys vector was given at young age (10 days after birth) ( Figure 3B ). These data suggest that the AAV1-cMinidys vector could protect muscle from histopathology, such as fibrosis, and prevent CN in neonatal mdx mice and partially reverse CN in adult mdx mice. These observations are in agreement with our previous human minidystrophin study 4 and studies from others. [6] [7] [8] [9] Canine minidystrophin protects myofiber membrane integrity Plasma membrane damage and leakage in dystrophic muscle tissue is a major pathological cause in DMD patients. The dystrophic muscle cell membranes become damaged and leaky during contraction and relaxation. To evaluate the efficacy of AAV1-cMinidys vector, it was important to see whether the plasma membrane of treated muscle cells can be protected. At 1 and 3 months post-AAV vector injection, a myofiber integrity test was performed by intravenous administration of Evans Blue dye (EBD) into the mdx mice and followed by swimming for half an hour. EBD is a widely used vital red fluorescent dye that is excluded by healthy myofibers, but is taken up by dystrophic myofibers with the leaky cell membranes. As shown in Figure 4 , the untreated mdx muscle had extensive EBD leakage and the myofibers showed intense red fluorescence (panel a). As expected, the AAV-treated mdx muscles at 1 (panel b) and 3 months (panel c) post-vector injection showed extensive minigene expression and very few red fluorescent myofibers, which were also negative for dystrophin staining. These results support the physiological functionality of the AAV1-cMinidys vector in maintaining membrane integrity and protecting myofibers from contraction-induced damages.
Discussion
The purpose of this study is to clone a canine minidystrophin construct and test its functionality using Canine minidystrophin functional in mdx mice B Wang et al the mdx mouse model. Our laboratory and others have previously reported that AAV vector-mediated delivery of mini-or microdystrophins of human origin was effective and functional in improving muscle pathology and protected myofiber membrane integrity in the mdx mouse model. 4, [6] [7] [8] [9] Although readily available and widely used, the mdx as a small rodent model has numerous limitations. The GRMD dog model, on the other hand, offers many advantages that the mdx mice lack, mainly the pathological similarity to those of DMD human patients, and a larger body mass for more accurate assessment of therapeutic vector dose. However, a major limitation of the dog model is its availability. Our initial attempts at applying AAV-human-minidystrophin to the Restoration of dystrobrevin, a-syntrophin and neural nitric oxide synthase (nNOS) shown similarly as above by immunofluorescent staining and counterstaining of the nuclei. The C57/BL10 mouse serves as control (panels a-d). Arrows in panels e-h highlight the same dystrophin revertant myofiber in consecutive thin-sections of untreated mdx mouse muscle. Panels m-p are the insert of panels i-l. Asterisks highlight the same myofiber in consecutive thin-sections of AAV1 vector-treated mdx muscle. Note the lower intensities of a-syntrophin and nNOS stainings in AAV1 vector-treated mdx muscle than the wild-type C57/B10 muscle.
Canine minidystrophin functional in mdx mice B Wang et al GRMD dogs was met with immune rejection (unpublished data), similar to the results reported by others. 13 We considered that the immune rejection of human minidystrophin in dog muscle tissues might be associated with species differences in the minidystrophin. The human minidystrophin and canine minidystrophin, used in our experiment, have a great percentage of difference in amino acids through the N terminus to the CR domain such as: N terminus (0.8%), hing1 (9.3%), rod1 (8.1%), rod2 (3.7%), rod 22 (6.1%), rod 23 (1.5%), rod 24 (6.4%), CR domain (0.3%), although they have the exactly same rods and hinges (Materials and methods).
To minimize the immune responses caused by interspecies antigenicity differences, we have cloned a canine minidystrophin gene and tested its functionality and therapeutic effects in the mdx mice before it can be further explored in the GRMD dog model, which not only has a very limited availability but also comes with a much higher requirement for vector dose and costs for humane use and care. Our results in this study have shown that the canine version of the minidystrophin is functional and therapeutic in the mdx mice, thus, paving its way for testing in the GRMD dogs. Intramuscular injection of AAV1-cMinidys vector in mdx mice, both neonates and adults, resulted in high-level expression without host cellular immune responses, consistent with previous results using human minidystrophin. 4 The expression of the canine protein correlated with the amelioration of dystrophic pathologies based on the presence of consistent myofiber size and shape, and lack of fibrosis in the minidystrophinpositive tissues. Improvement of a major pathological sign of muscle degeneration and regeneration, CN was also observed in myofibers expressing the canine minidystrophin. In mdx mice treated at adult age, a reduction (or reversal) of CN from more than 75% to about 25% of the myofibers was achieved as a result of canine minidystrophin expression, which is consistent Figure 3 Improvement of muscle histology in adeno-associated virus (AAV)1 vector-treated mdx mice. Adult mdx mice (2-month old) were injected with AAV1-cMinidys vector intramuscularly. (A) At 1 and 3 months after vector injection, the muscles were collected, crosssectioned, and subject to immunofluorescent staining, dystrophin and 4,6-diamidino-2-phenylindole (DAPI) counterstaining (panels a-d) or hematoxylin and eosin (H & E) staining for histology (panels e-h). Muscle histology in AAV1-cMinidys-treated mdx mice had significant improvement when compared to the untreated mdx. Note that centrally localized nuclei in the vector-treated mdx mice were reduced but not completely reversed to the peripheral position. (B) Quantitative analysis of central nucleation of myofibers of untreated legs (black bars) and AAV-treated legs (red bars) at 1 and 3 months after vector injection in adult (2-month old) and neonatal (10-days old) mdx mice. Normal C57/B10 myofibers had about 1% central nucleation (CN) (data not shown). The numbers were collected from 600 to 900 minidys-positive myofibers of AAV-treated legs or minidystrophin negative ones of the untreated legs of four mice in each group (n ¼ 4).
Canine minidystrophin functional in mdx mice B Wang et al with a previous report with a human microdystrophin. 6 In mdx mice treated at young age (10 days after birth), a near complete prevention of CN was achieved. EBD test demonstrated that the canine minidystrophin could offer protection to myofiber plasma membrane integrity during exercise, again consistent with previous published observations with human mini-or microdystrophins.
Of particular interest in this study is the detection of partial restoration of nNOS on the sarcolemma of mdx muscle, as part of the DPC. Dystrophin acts as a linchpin in holding all the components together on DPC. Miniand microdystrophin have been previously shown to restore a majority of the missing components of DPC on the mdx sarcolemma. Those components include dystroglycans, sarcoglycans, sarcospan and dystrobrevin. 16, 17 However, restoration of nNOS has not been previously detected after microdystrophin expression in dystrophindeficient mouse muscle 18 and the reasons remain elusive. In our previous studies, we did not make the effort to detect the restoration of nNOS. 4 However, in this study, we indeed detected partial restoration of nNOS and its binding protein a-syntrophin ( Figure 2B ). This was initially unexpected as both mini-and microdystrophins lack the entire distal C-terminal domain, which is the binding site for a-syntrophin, and indirectly for nNOS (Figure 5a ). However, as syntrophin, and hence nNOS, can also bind to dystrobrevin, 19 which is also missing in mdx muscle, we speculated that restoration of dystrobrevin could partially restore the syntrophin-nNOS onto the DPC (Figure 5b) . It was indeed our observation. This could explain why we consistently observed weaker immunostaining of the nNOS and syntrophin in minidystrophin-positive myofibers than in wild-type myofibers ( Figure 2B ), as only a partial restoration was expected (Figure 5b) . A previous study indicated that the rod domain encoded by exons 45-48 of the dystrophin gene was required for localization of nNOS to the sarcolemma. 20 However, Crosbie et al., 21 reported that a minidystrophin (from a Becker MD patient) missing exons 17-48 was able to restore nNOS to the sarcolemma in transgenic mdx mice, and also, the deletion of exons 71-74 or exons 75-78 of the C-terminal region in transgenic mice did not affect the expression of nNOS. Our canine minidystrophin construct (containing exons 1-14 and exons 55-70), which lacked exons 15-54 and Figure 4 Protection of myofiber embrane Integrity. In vivo Evans blue dye (EBD) test was performed at 1 and 3 months after vector injection in the hindlegs of 10-day-old mdx mice (See Materials and methods). Gastrocnemius muscles of untreated control mdx mice (a) had extensive EBD leakage (red color) into the myofibers without dystrophin staining (green color). However, muscles of vector-treated mdx mice at 1-month (b) and 3-months (c) post-adeno-associated virus (AAV)1-cminidys injection displayed widely distributed minidystrophin expression (green color) and few EBD-positive myofibers, which are minidys negative. Nuclei are counterstained with 4,6-diamidino-2-phenylindole (DAPI) (Blue). Figure 5 Schematic models of syntrophin and neural nitric oxide synthase (nNOS) binding on the dystrophin-associated protein complex (DPC) on sarcolemma of normal myofiber and minidystrophin-expressing mdx myofibers. In normal myofibers, syntrophin and nNOS bind to the C termini of both dystrophin and dystrobrevin (a). In minidys-expressing mdx myofibers, however, syntrophin and nNOS could only bind to the C terminus of dystrobrevin (b), because the minidystrophin lacks the entire C terminus of the wild-type dystrophin (see Figure 1 for more detail).
Canine minidystrophin functional in mdx mice B Wang et al exons 71-79, was also able to restore nNOS to the sarcolemma, and therefore supports the latter report. 21 Although nNOS does not play a major role in DMD pathology, 21, 22 its normal submembrane location in myofibers is believed to facilitate microcapillary blood vessel dilation during exercises. 23 It may also play some role in yet to be defined signal-transduction pathways. nNOS gene knockout in mdx mice does not exacerbate the dystrophic phonotype. 21 However, forced overexpression of nNOS is reported to reduce muscle pathology in mdx mice primarily by keeping inflammation in check. 24 In DMD and mdx muscles, the nNOS has lost its submembrane anchor and become diffused and diminished in the cytoplasma of the myofibers. After minidystrophin gene expression in the mdx muscle, we have observed profound improvement in dystrophic pathology. However, how significant a contribution made by the partial restoration of nNOS in this case remains to be elucidated.
In conclusion, these studies have shown successful expression of canine minidystrophin in mdx mice, and that this expression correlated with improvement and prevention of dystrophic pathologies. These data have paved the way for further investigation of the canine minidystrophin gene in gene therapy studies in the GRMD animal model.
Materials and methods
Cloning and construction of canine minidystrophin cDNA and AAV vector production Canine minidystrophin cDNA was generated using reverse transcription-PCR techniques and a series of cloning processes from normal canine muscle tissues provided by Dr Kornegay's laboratory (University of Missouri-Columbia, Columbia, MO, USA). Total RNA was extracted from the canine muscle samples (Trizol, Invitrogen, Carlsbad, CA, USA) and the cDNA was synthesized by reverse transcription (ThermoScript RT-PCR System, Invitrogen). The N terminus and C terminus of the canine dystrophin cDNA were generated separately and cloned into pBluescriptII KS(+) vectors (Stratagene, La Jolla, CA, USA). The primers utilized for amplification of the N terminus were 5 0 -ATG CTTTGGTGGGAAGAAGTAGAGG and 5 0 -ATCCAC GATAATCTGCCTC. The primers utilized for the C terminus were 5 0 -ACCCACAGATTACTGCAAC and 5 0 -CTAAGTTTCCATGTTGTCCCCC. The N-and C-terminal portions of the canine minidystrophin genes were then joined in-frame by a PCR-mediated strategy. Similar to the human minidystrophin gene, the in-frame deleted minidystrophin cDNA contained the N terminus, hinge1, rods (1, 2, 22, 23, 24) , hinge 4 and CR domain (Figure 1a ). The final construction was carefully sequenced and all the essential domains were verified according to the reported canine dystrophin cDNA (GeneBank AF070485). The resulting canine minidystrophin cDNA was then cloned into an AAV vector driven by the CMV promoter. The recombinant viral vector stocks were produced according to the three-plasmid cotransfection method. 25 The viral particles were purified twice by CsCl density gradient ultracentrifugation using the previously published protocol. 26 The vector titers (vector genome, v.g.) were determined by DNA dot-blot method, and were in the range of 2 Â 10 12 to 5 Â 10 12 v.g. per ml. The final vector was named AAV1-CMV-cMinidys.
Western analysis for the evaluation of canine minidystrophin expression in 293 cells in vitro
Western blot analyses were used to evaluate the expression of canine minidystrophin in 293 cells in vitro. The 293 cells, a human embryonic kidney cell line, was grown in Dulbecco modified eagle's medium (Invitrogen) with 10% heat-inactivated fetal bovine serum (Invitrogen). Before transfection, the density of 293 cells was allowed to reach 80-85% in six-well culture plates. In each well, the transfection was performed in 1.5 ml of Iscove Modified Dulbecco Medium (Invitrogen) containing 10% fetal bovine serum without antibiotics, and a total of 3 mg of plasmid DNA applied to each well using the previously published calcium phosphate transfection method.
25 At 7-8 h post-transfection, the medium was removed and replaced with Dulbecco modified eagle's medium containing 10% fetal bovine serum and antibiotics (Penn/Strep). Twenty-four hours after transfection, the cells were harvested and lysed in 100 ml of radioimmunoprecipitation assay buffer (10 mM Tris-HCl pH8.2, 1% Triton X-100, 1% SDS and 150 mM NaCl). The western blot analysis was performed as described before 5 utilizing polyclonal antibody directed against the rods 1 and 2 region of human dystrophin, which has cross-reaction with canine dystrophin (1:5000).
AAV vector injection and EBD test in mdx mice
Mdx mice were purchased from Jackson Laboratories and were handled in accordance with guidelines of the Administrative Panel on laboratory Animal care of the University of Pittsburgh. For adult mdx mice (2 months of age), the AAV1-cMinidys vector was administered to one side of the gastrocneminus muscle at a volume of 50 ml (total 1.25 Â 10 11 v.g. particles) per injection, and the untreated contralateral side served as a negative control. For the young mdx mice (10-day-old male pups), 30 ml of the AAV1-cMinidys vector (total 7.5 Â 10 10 v.g. particles) was injected into the gastrocneminus muscle and the untreated contralateral side served as a negative control. The vector-treated young and adult mdx mice were analyzed at 1 and 3 months post-treatment, respectively. For myofiber plasma membrane integrity test, EBD (1 mg/10 g mouse body weight) was injected into the mice through tail vein. The mice were then subject to swimming for half an hour in 30 1C water bath and killed 6 h later. 4 Immunofluorescent staining of muscle cross-thin-sections At 1 and 3 months post-treatment, both injected and contralateral untreated gastrocneminus muscles were harvested and snap frozen in liquid nitrogen-cooled isopentane. The muscles were then cryosectioned (10 mm thickness) and immunostained without prior fixation. Polyclonal primary antibodies were used for immunostaining of dystrophin (anti-rod1 and 2 regions of human dystrophin, 1:500), dytrobrevin (Abcam, Cambridge, MA, USA, 1:1000) and a1-syntrophin (Abcam, 1:500). Monoclonal primary antibodies were used for the immunostaining of the a-, b-and g-sarcoglycans Canine minidystrophin functional in mdx mice B Wang et al (NCL-a-SARC, NCL-b-SARC, NCL-g-SARC, 1:100; Novocastra, Newcastle, UK), and the staining was performed using the Vector M.O.M Immunodetection Kit (Vector Laboratories, Burlingame, CA, USA). The nNOS polyclonal antibody (N terminal) was purchased from ImmunoStar and diluted at 1:100. The immunostaining and hematoxylin and eosin staining processes were conducted as previously described. 5, 27 The secondary antibodies used in these studies were Alexa Fluor 488 chicken anti-rabbit IgG (1:500 dilution/green color) and goat anti-rabbit IgG (whole molecule) Peroxidase Conjugate (1:500 dilution/red color), purchased from Molecular Probes (Eugene, OR, USA) and Sigma Chemical Company (St Louis, MO, USA).
